FCMI
KDNY

Foresite Capital Management II’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Foresite Capital Management II’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-264,583
Closed -$16.9M – 18
2016
Q1 		$16.9M Sell
264,583
-66,816
-20% -$5.4M 8.29% 3
2015
Q4 		$46.6M Sell
331,399
-89,948
-21% -$12.2M 15.63% 2
2015
Q3 		$40.8M Hold
421,347
– – 12.39% 2
2015
Q2 		$63.9M Buy
+421,347
New +$69.6M 22.42% 1

Other funds holding KDNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Foresite Capital Management II's KDNY Position: Q2 2016 in Review

Foresite Capital Management II sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2016, closing a stake of 264,583 shares — an estimated $16.9M sold.

Foresite Capital Management II first reported a position in KDNY in Q2 2015 and held it in 4 quarters. The position peaked at $63.9M in Q2 2015. 102 funds tracked by Wall St. Rank hold KDNY as of Q2 2016.

  • Foresite Capital Management II reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Foresite Capital Management II sold 264,583 Chinook Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $16.9M.
  • Foresite Capital Management II first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 4 quarters.
  • Foresite Capital Management II's Chinook Therapeutics, Inc. Common Stock position peaked at $63.9M in Q2 2015.
  • 102 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Foresite Capital Management II's 13F filing for Q2 2016, filed 12 Aug 2016.